Cancer Family
Osteogenic Neoplasm
CI-CAN-00000304Explore in graph →
Non-malignant101 active trials6 approved drugs8 evidence items
- NCIt
- C6603
Loading cancer entity…
Cancer Family
CI-CAN-00000304Explore in graph →
Clinical trials
357 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07774533 | 68Ga-B7-H3 Nanobody ImmunoPET in Osteosarcoma | recruiting | Early Phase 1 | 16 | Peking University First HospitalOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07628634 | Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors | recruiting | Early Phase 1 | 25 | University of California, IrvineOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT03960177 |
| Glucarpidase After High-Dose Methotrexate in Patients With Osteosarcoma |
| completed |
| Early Phase 1 |
| 11 |
| OHSU Knight Cancer InstituteOTHER |
| 1 |
| Jul 7, 2026 |
| clinicaltrials |
| NCT06645808 | PET-imaging of Two Vartumabs in Patients With Solid Tumors(VARTUTRACE) | recruiting | Early Phase 1 | 32 | Var2 PharmaceuticalsINDUSTRY | 1 | Dec 29, 2025 | clinicaltrials |
| NCT06171282 | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Bone and Soft Tissue Tumors | unknown | Early Phase 1 | 9 | Shanghai Yunying Medical TechnologyINDUSTRY | 1 | Dec 14, 2023 | clinicaltrials |
| NCT06117878 | Safety and Efficacy of NK510 to Treat Osteosarcoma and Soft Tissue Sarcoma | unknown | Early Phase 1 | 12 | Base Therapeutics (Shanghai) Co., Ltd.INDUSTRY | 1 | Nov 7, 2023 | clinicaltrials |
| NCT05851456 | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Bone and Soft Tissue Tumors | unknown | Early Phase 1 | 20 | Shanghai Yunying Medical TechnologyINDUSTRY | 1 | May 9, 2023 | clinicaltrials |
| NCT04864821 | Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor | unknown | Early Phase 1 | 24 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 0 | May 6, 2021 | clinicaltrials |
Data updated 22 days agoSource updated Aug 19, 2026source: clinicaltrials